---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-000285"
form_type: "8-K"
ticker: "FNCHQ"
cik: "0001733257"
company_name: "Finch Therapeutics Group, Inc."
filed_at: "2023-01-06T23:59:59+00:00"
generated_at: "2026-06-20T18:53:05.832713+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Finch Therapeutics receives Nasdaq deficiency notice for bid price below $1.00

## Summary
- Received Nasdaq deficiency letter on Dec 30, 2022 for non-compliance with $1.00 minimum bid price requirement.
- Has 180 calendar days (until June 28, 2023) to regain compliance by closing at $1.00+ for 10 consecutive days.
- May be eligible for additional 180-day extension if it transfers listing to Nasdaq Capital Market.
- Company may consider a reverse stock split to regain compliance, subject to board and shareholder approval.
- No assurance compliance will be regained; failure could lead to delisting.

## SEC filing metadata
- accession: 0000950170-23-000285
- form_type: 8-K
- ticker: FNCHQ
- cik: 0001733257
- company_name: Finch Therapeutics Group, Inc.
- filed_at: 2023-01-06T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1733257/000095017023000285/0000950170-23-000285-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1733257/000095017023000285/fnch-20230106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-000285
- JSON: https://secwatch.observer/filing/0000950170-23-000285.json
- Plain text: https://secwatch.observer/filing/0000950170-23-000285.txt

## Key facts
- Listing & Compliance Notices
  Finch Therapeutics Group, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1)
  source text: December 30, 2022, Finch Therapeutics Group, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock, par value $ 0.001 per share (the “Common Stock”), had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). The deficiency letter has no immediate effect on the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1733257/000095017023000285/0000950170-23-000285-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.